Assessing Optimal XR-Buprenorphine Initiation Points in Jail
Opioid Use Disorder
About this trial
This is an interventional health services research trial for Opioid Use Disorder focused on measuring XR-Buprenorphine, Sublocade, Medication for Opioid Use Disorder (MOUD)
Eligibility Criteria
Inclusion Criteria:
- Incarcerated adults able to provide written informed consent in English.
- Currently sentenced with pending release date between 3-7 months.
- Current moderate-to-severe opioid use disorder (DSM-5)
- Reasonable likelihood of completing 3-months or longer of community treatment (i.e., no plans to be transferred out of state or to another correctional facility)
- Willing to accept being randomized to initiating XR-B treatment at the time of jail admission or near the time of release.
Exclusion Criteria:
- Severe medical or psychiatric disability making participation unsafe or regular follow-up unlikely, including patients with pre-existing moderate to severe hepatic impairment are not eligible to participate
- Pregnancy, planning conception, or breast-feeding
- Allergy, hypersensitivity or medical contraindication to either medication
- Chronic pain requiring opioid pain management
- On methadone or buprenorphine (SL-B) maintenance prior to incarceration AND intending to remain on methadone or buprenorphine maintenance upon return to the community.
Sites / Locations
- NYU Langone Health
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
XR-B Induction at Admission
XR-B Induction at Pre-Release
Participants will initiate extended-release buprenorphine (XR-B) treatment at the time of admission. XR-B will be continued monthly from the time of induction to the day of release (up to 6 months), and up to 3 monthly injections will be offered in the community following release. Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly.
Participants will initiate extended-release buprenorphine (XR-B) treatment within 30 days of release. Participants will receive at least one XR-B monthly injection prior to release, and XR-B will be continued monthly from the time of induction to the day of release. Up to 3 monthly injections will be offered in the community following release. Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly.